207 related articles for article (PubMed ID: 32981916)
1. Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.
Yamashita T; Vollbrecht C; Hirsch B; Kleo K; Anagnostopoulos I; Hummel M
J Clin Exp Hematop; 2020; 60(3):87-96. PubMed ID: 32981916
[TBL] [Abstract][Full Text] [Related]
2. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
3. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
4. Indolent In Situ B-Cell Neoplasms With MYC Rearrangements Show Somatic Mutations in MYC and TNFRSF14 by Next-generation Sequencing.
Kumar J; Butzmann A; Wu S; Easly S; Zehnder JL; Warnke RA; Bangs CD; Jangam D; Cherry A; Lau J; Nybakken G; Ohgami RS
Am J Surg Pathol; 2019 Dec; 43(12):1720-1725. PubMed ID: 31368914
[TBL] [Abstract][Full Text] [Related]
5. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
6. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
Ott G; Rosenwald A; Campo E
Blood; 2013 Dec; 122(24):3884-91. PubMed ID: 24009228
[TBL] [Abstract][Full Text] [Related]
7. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
8. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
9. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
10. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
Kim H; Kim HJ; Kim SH
Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
[TBL] [Abstract][Full Text] [Related]
12. The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas.
Soldini D; Georgis A; Montagna C; Schüffler PJ; Martin V; Curioni-Fontecedro A; Martinez A; Tinguely M
Hematol Oncol; 2014 Sep; 32(3):120-5. PubMed ID: 24493312
[TBL] [Abstract][Full Text] [Related]
13. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas.
Behdad A; Bailey NG
Surg Pathol Clin; 2016 Mar; 9(1):41-54. PubMed ID: 26940267
[TBL] [Abstract][Full Text] [Related]
15. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry.
Mandelker DL; Dorfman DM; Li B; Pozdnyakova O
Leuk Lymphoma; 2014 Nov; 55(11):2592-6. PubMed ID: 24397618
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
[TBL] [Abstract][Full Text] [Related]
17. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
Tian X; Pelton A; Shahsafaei A; Dorfman DM
Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
[TBL] [Abstract][Full Text] [Related]
19. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
20. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
